Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy
This work has been supported by grants from CIBERNED (CB06/05/0089 to JF-R), MICINN (PID2021-128906OB-I00 to JF-R, PID2022-139936OA-I00 to EN and PID2022-137065OB-I00 to ILB) with FEDER funds and Michael J. Fox Foundation (MJFF-022552 to JF-R). These agencies had no further role in study design, the...
| Autores: | , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/383477 |
| Acceso en línea: | http://hdl.handle.net/10261/383477 |
| Access Level: | acceso abierto |
| Palabra clave: | VCE-003.2 Parkinson’s disease Alpha-synuclein Cannabinoids PPAR-γ |
| Sumario: | This work has been supported by grants from CIBERNED (CB06/05/0089 to JF-R), MICINN (PID2021-128906OB-I00 to JF-R, PID2022-139936OA-I00 to EN and PID2022-137065OB-I00 to ILB) with FEDER funds and Michael J. Fox Foundation (MJFF-022552 to JF-R). These agencies had no further role in study design, the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. Sonia Burgaz was a predoctoral fellow supported by the Complutense University, whereas Santiago Rodríguez-Carreiro was supported by the Ministry of University (FPU Programme). |
|---|